Lantheus Holdings, Inc. $LNTH Stock: University of Texas Texas AM Investment Management Co. Raises Position

University of Texas Texas AM Investment Management Co. boosted its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 1,508.4% during the 3rd quarter, Holdings Channel reports. The fund owned 19,043 shares of the medical equipment provider’s stock after acquiring an additional 17,859 shares during the quarter. University of Texas Texas AM Investment Management Co.’s holdings in Lantheus were worth $1,895,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the company. Jupiter Topco LLC acquired a new stake in shares of Lantheus in the 2nd quarter valued at $575,628,000. Assenagon Asset Management S.A. lifted its position in shares of Lantheus by 440.3% during the 2nd quarter. Assenagon Asset Management S.A. now owns 714,980 shares of the medical equipment provider’s stock worth $79,320,000 after purchasing an additional 582,661 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund grew its stake in shares of Lantheus by 686.1% during the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 598,857 shares of the medical equipment provider’s stock worth $45,423,000 after purchasing an additional 522,678 shares in the last quarter. Summit Street Capital Management LLC acquired a new position in shares of Lantheus during the second quarter worth $44,454,000. Finally, Defilade Capital Management L.P. purchased a new position in Lantheus in the first quarter valued at $18,917,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Price Performance

Lantheus stock opened at $100.61 on Monday. Lantheus Holdings, Inc. has a twelve month low of $50.15 and a twelve month high of $111.86. The stock has a 50 day moving average of $100.27 and a two-hundred day moving average of $92.06. The company has a current ratio of 3.25, a quick ratio of 3.06 and a debt-to-equity ratio of 0.42. The stock has a market capitalization of $6.57 billion, a price-to-earnings ratio of 24.78 and a beta of 0.01.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, November 5th. The medical equipment provider reported $1.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.23 by $0.45. The business had revenue of $389.91 million for the quarter, compared to analyst estimates of $355.74 million. Lantheus had a return on equity of 29.26% and a net margin of 17.28%. The company’s revenue for the quarter was up 1.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.27 earnings per share. As a group, research analysts expect that Lantheus Holdings, Inc. will post 4.54 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have issued reports on LNTH. Weiss Ratings downgraded Lantheus from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, October 15th. Brookline Capital Markets cut Lantheus from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. William Blair set a $102.50 price objective on Lantheus in a report on Monday, August 3rd. Mizuho lowered Lantheus from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $115.00 to $109.00 in a research report on Tuesday, October 13th. Finally, Truist Financial lowered Lantheus from a “buy” rating to a “hold” rating and cut their target price for the stock from $125.00 to $102.50 in a research report on Monday, August 3rd. Three research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $107.44.

Lantheus Company Profile

Lantheus Holdings is a radiopharmaceutical and medical imaging company that develops, manufactures, and commercializes products used to diagnose and manage disease. Its offerings support imaging across several areas of medicine, including oncology and cardiology.

The company’s products include Pylarify, a positron emission tomography (PET) imaging agent used to detect prostate cancer; Definity, an ultrasound contrast agent used in cardiac imaging; and TechneLite, a generator that supplies technetium-99m for diagnostic imaging procedures.